van der Willik, Kimberly D.
Koppelmans, Vincent
Hauptmann, Michael
Compter, Annette
Ikram, M. Arfan
Schagen, Sanne B.
Funding for this research was provided by:
KWF Kankerbestrijding (NKI-20157737)
Article History
Received: 7 June 2018
Accepted: 12 October 2018
First Online: 15 November 2018
Ethics approval and consent to participate
: Breast cancer survivors: Written informed consent was obtained from all participants. The institutional review boards of the two participating institutions (the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and the Erasmus University Medical Center) approved the study.Rotterdam Study: The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272–159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (ExternalRef removed) and the WHO International Clinical Trials Registry Platform (ExternalRef removed) under shared catalogue number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.